Sanara MedTech (SMTI)
NASDAQ:SMTI
Want to see SMTI full AI Analyst Report?
SMTI Stock Chart & Stats
$29.52
$0.13(0.40%)
At close: 4:00 PM EST
$29.52
$0.13(0.40%)
Day’s Range― - ―
52-Week Range$16.05 - $35.95
Previous CloseN/A
Volume5.72K
Average Volume (3M)61.65K
Market Cap
$194.83M
Enterprise Value$243.62M
Total Cash (Recent Filing)$13.59M
Total Debt (Recent Filing)$48.37M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Aug 17, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.90
Shares Outstanding9,163,969
10 Day Avg. Volume48,775
30 Day Avg. Volume61,645
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)33.96
Price to Sales (P/S)1.95
P/FCF Ratio93.17
Enterprise Value/Market Cap1.25
Enterprise Value/Revenue2.27
Enterprise Value/Gross Profit2.49
Enterprise Value/Ebitda21.28
Forecast
1Y Price Target
$34.00Price Target Upside15.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.12
Revenue Forecast (FY)$117.30M
Bulls Say, Bears Say
Bulls Say
Gross Margin StrengthVery high and improving gross margins (~93%) indicate durable product-level economics across the wound-care portfolio. Such strong margins provide structural resilience to pricing pressure, support reinvestment in sales and R&D, and create a persistent buffer to help service debt and fund growth.
Improving Cash GenerationSustained positive operating and free cash flow is a durable improvement that reduces reliance on external capital. Positive FCF enables the company to pay cash interest and principal, prioritize organic growth and R&D (OsStic pipeline), and materially lowers refinancing pressure if maintained over ensuing quarters.
Distribution & Commercial ScaleA broad commercial footprint and growing distributor base create structural advantages in adoption and repeatable revenue. Scale across thousands of facilities and a larger salesforce supports cross-selling, faster rollouts of new products, and more predictable demand as contracts and GPO relationships mature.
Bears Say
High LeverageExtremely elevated debt-to-equity materially limits financial flexibility and raises refinancing and dilution risk. High leverage increases sensitivity to interest rates and cash shortfalls, constraining M&A or big commercial investments until sustained deleveraging or equity accretion occurs.
Persistent Net LossesDespite operating progress, sizable net losses show below-the-line costs still overwhelm operating gains. Continued negative net margins erode equity, raise dilution risk, and mean GAAP profitability is not yet durable; the company must sustain operating gains to convert to lasting bottom-line strength.
Rising Interest & SG&A PressureHigher interest costs and rising SG&A from an expanding salesforce increase ongoing cash demands and can offset margin improvements. If revenue accretion from hires and GPO partnerships lags expected timing, these elevated expenses could slow deleveraging and stress free cash flow sustainability.
Sanara MedTech News
SMTI FAQ
What was Sanara MedTech’s price range in the past 12 months?
Sanara MedTech lowest stock price was $16.05 and its highest was $35.95 in the past 12 months.
What is Sanara MedTech’s market cap?
Sanara MedTech’s market cap is $194.83M.
When is Sanara MedTech’s upcoming earnings report date?
Sanara MedTech’s upcoming earnings report date is Aug 17, 2026 which is in 74 days.
How were Sanara MedTech’s earnings last quarter?
Sanara MedTech released its earnings results on May 11, 2026. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of -$0.13 by $0.17.
Is Sanara MedTech overvalued?
According to Wall Street analysts Sanara MedTech’s price is currently Undervalued.
Does Sanara MedTech pay dividends?
Sanara MedTech does not currently pay dividends.
What is Sanara MedTech’s EPS estimate?
Sanara MedTech’s EPS estimate is -0.03.
How many shares outstanding does Sanara MedTech have?
Sanara MedTech has 9,163,969 shares outstanding.
What happened to Sanara MedTech’s price movement after its last earnings report?
Sanara MedTech reported an EPS of $0.04 in its last earnings report, beating expectations of -$0.13. Following the earnings report the stock price went up 13.43%.
Which hedge fund is a major shareholder of Sanara MedTech?
Currently, no hedge funds are holding shares in SMTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sanara MedTech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$34.00 (15.18% Upside)
$34.00 (15.18% Upside)
Blogger Sentiment
Bullish
SMTI Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.65%
12-Months-Change
Fundamentals
Return on Equity
-246.44%
Trailing 12-Months
Asset Growth
-28.12%
Trailing 12-Months
Company Description
Sanara MedTech
Sanara MedTech Inc. (SMTI) is a medical technology company focused on developing and commercializing advanced wound care and regenerative medicine products. The company operates primarily in the healthcare sector, offering innovative solutions designed to improve patient outcomes and promote healing in chronic and acute wounds. Sanara's core product portfolio includes advanced wound dressings and bioactive solutions that utilize its proprietary technologies to facilitate tissue regeneration and healing processes.
SMTI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive picture: the company delivered strong top-line growth (19% YoY), improved margins, positive GAAP net income, and sizable adjusted EBITDA improvement while expanding commercial reach and reaffirming full-year guidance. Key concerns noted were modest cash reduction, higher interest/other expenses, increased SG&A, and that new sales hires and the Vizient contract will take time to be fully accretive. On balance, the positives (growth, profitability, margin expansion, distribution scale, and cash-based debt servicing) materially outweigh the headwinds.View all SMTI earnings summariesSMTI Stock 12 Month Forecast
Average Price Target
$34.00
▲(15.18% Upside)
Technical Analysis
InfuSystem Holdings
―
Orasure Technologies
―
Stereotaxis
―
Utah Medical Products
―
Sharps Technology, Inc.
―
Ownership Overview
2.02% Insiders
3.01% Mutual Funds
1.81% Other Institutional Investors
89.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---